



July 23, 2021

National Stock Exchange of India Limited
Exchange Plaza, C-1 Block G
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051, India

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400001, India

Ref: Jubilant Pharmova Limited

Scrip Code: 530019

Symbol: JUBLPHARMA

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Approval of the Scheme of Arrangement

Dear Sir/ Madam,

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Jubilant Pharmova Limited (“**JPM**”), at its meeting held on July 23, 2021, has approved the demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited (“**JGL**” - a wholly owned subsidiary of the Company) and vesting of the same with JPM, on a going concern basis (“**Proposed Demerger**”), to be implemented through a scheme of arrangement between JGL and JPM and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (“**Proposed Scheme**”).

The details as required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated September 9, 2015, are enclosed at ‘Annexure A’.

Kindly take the above information on record.

Thanking you,
Sincerely yours,

For Jubilant Pharmova Limited

Rajiv Shah
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624

Annexure A

**Details as required to be disclosed under Regulation 30 read with
the SEBI Circular dated September 9, 2015**

Demerger of the Active Pharmaceutical Ingredients undertaking (“API Undertaking”) of Jubilant Generics Limited (“JGL”) and vesting of the same with Jubilant Pharmova Limited (“JPM”), on a going concern basis:

Sr. No.	Particulars	Details
a)	Brief details of the division(s) to be demerged.	The API Undertaking of JGL i.e. the business division engaged in the research, development, manufacture, sale, distribution, marketing and supply of active pharmaceutical ingredients, such undertaking to be more particularly described in the Proposed Scheme.
b)	Turnover of the demerged division and as percentage to the total turnover of the listed entity in the immediately preceding financial year / based on financials of the last financial year.	<ul style="list-style-type: none"> • <u>Turnover of API Undertaking for FY 2020-21: Rs. 596 Crore</u> • <u>Percentage to the Total Consolidated Turnover of JPM for FY 2020-21: 9.77%</u>
c)	Rationale for demerger	The Proposed Demerger will <i>inter alia</i> result in better operational synergy and management effectiveness.
d)	Brief details of change in shareholding pattern (if any) of all entities	Since the Proposed Demerger does not envisage the issuance of shares, there will be no change in shareholding consequent to implementation of the Proposed Demerger.
e)	In case of cash consideration - amount or otherwise share exchange ratio	The Proposed Demerger does not envisage the issuance of shares nor payment of cash consideration.
f)	Whether listing would be sought for the resulting entity	The equity shares of the resulting company (i.e. JPM) are currently listed on the BSE Limited and the National Stock Exchange of India limited.

A Jubilant Bhartia Company

OUR VALUES



Jubilant Pharmova Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantpharmova.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
UP, India
CIN : L24116UP1978PLC004624